Home Medical Devices Injectable Drugs Market Growth, Trends and Forecast to 2031

Injectable Drugs Market

Injectable Drugs Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Drug Class (Blood Factors, Cytokines, Peptide Hormone, Immunoglobulin, Monoclonal Antibodies (MABS), Insulin, Other Drug Classes), By Applications (Oncology, Neurology, Cardiovascular Diseases, Autoimmune Diseases, Infectious Diseases, Pain, Other Applications) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRMD54231DR
Study Period 2019-2031 CAGR 7.95%
Historical Period 2019-2021 Forecast Period 2023-2031
Base Year 2022 Base Year Market Size USD 464.40 Billion
Forecast Year 2031 Forecast Year Market Size USD 924.48 Billion
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global injectable drugs market size was valued at USD 464.40 billion in 2022. It is projected to reach USD 924.48 billion by 2031, growing at a CAGR of 7.95% during the forecast period (2023-2031). 

A syringe and needle are used to inject medications into the body. These medications are used to treat a range of illnesses and conditions. Increased use of injectable medications by people with chronic illnesses such as cardiovascular disease, autoimmune and inflammatory disorders, cancer, and infectious diseases is anticipated to fuel market expansion. For instance, there has been a growing need for cardiovascular disease prevention and therapy over time. In addition, the World Health Organization projects that the leading cause of death globally in 2021 will be cardiovascular diseases (CVDs). Also, 17.9 million people are thought to suffer from cardiovascular disorders annually. Strokes and heart attacks account for four out of every five cardiovascular deaths, and one-third of all deaths occur prematurely or in those under 70.


  • The large molecule segment is the highest contributor to the market by molecule type.
  • The monoclonal antibodies (MABS) segment is the highest contributor to the market by drug class.
  • The infectious diseases segment is the highest contributor to the market by application.
  • North America is the major revenue contributor by region.

Market Dynamics

Global Injectable Drugs Market Drivers

Increasing R&D Focus on the Development of Biotechnology-Engineered Anti-Cancer Drugs

Bio-engineered medications are proteins or peptides that the body cannot absorb properly when taken orally. Therefore, these medications are continuously injected over long periods. The industry growth is anticipated to be boosted by rising cancer incidence, increasing R&D efforts, and rising releases of bioengineered medications. Over time, there has been a rise in the demand for cancer treatment and prevention. Each year, more than 11 million people receive a cancer diagnosis. By 2040, this is anticipated to rise to 30.2 million new cancer cases. The market for injectable pharmaceuticals is ultimately driven by the need for biotechnology-engineered anti-cancer therapies, which is increasing as cancer cases increase.

Global Injectable Drugs Market Restraint

High Costs Resulting from Inventory Management

Managing pharmaceutical inventory in a dynamic supply chain environment is challenging due to product shortages, demand variations, and recalls. The intricacy of this task is increased when developing inventory management plans for biologics. The shelf life of some of the medications is shorter. The management of injectable drug inventories is challenging for pharmaceutical and biotech organizations. To guarantee that all clients have access to the product at all times, at all prices, and in all reasonable conditions. This results in high inventory management costs for injectable pharmaceuticals, limiting the market's expansion.

Most pharmaceutical and biotech organizations need help selecting an inventory and warehouse management system because of the level of compliance required. Software created expressly for the biopharmaceutical business is required to preserve injectable pharmaceuticals' shelf life and storage. Still, its high cost is a barrier to the market's expansion.

Global Injectable Drugs Market Opportunities

Expanding Use of Prefilled Syringes for Biological Products

The development of self-injecting parenteral devices and the rise in their use are both responsible for the demand for prefilled syringes. Patients and healthcare professionals are becoming more aware of the advantages of prefilled syringes; more biologics are on the market, more sophisticated biologic medications are being developed, and drug delivery systems like prefilled syringes are being tailored to meet the challenges.

Parenteral medication delivery has some drawbacks, including price, lack of convenience, precision, sterility, safety, etc. This distribution system's shortcomings make it less desirable. Thus, using prefilled syringes allowed for eliminating all the drawbacks of these methods. Therefore, in recent years, pharmaceutical and biotechnology businesses have been interested in developing biotechnology goods like therapeutic proteins or vaccines in prefilled syringes (PFS).

Regional Analysis

The global injectable drugs market share is divided into four regions: North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the major revenue contributor and is expected to grow at a CAGR of 7.70% during the forecast period. The main drivers propelling market expansion in the US are the rising prevalence of chronic diseases nationwide and the quick uptake of vaccines for various diseases. Several patients have been hospitalized and have used injectable drugs as a form of treatment as a result of rising per capita health spending, improvements in the healthcare infrastructure, the accessibility of insurance policies, and the rise in infectious disease and chronic disease cases in the nation. Introducing new items into the market is another area of emphasis for the industry participants. For instance, Teriparatide Injection was introduced in the United States on June 12, 2020, by Pfenex Inc.'s commercialization partner Alvogen.

Europe is expected to boost at a CAGR of 8.05% during the forecast period. Due to the increased prevalence of numerous chronic diseases and the country's aging population, Germany has many international businesses focusing on developing medicines, which is projected to fuel market expansion. The prevalence of chronic diseases is high in the nation. The primary causes of death are cardiovascular disorders, cancer, and respiratory conditions. According to a Federal Statistical Office (Destatis) study from 2021, over 231,000 persons in Germany died from cancer in 2019, including about 125,000 males and 106,000 women. Over a 20-year span, this percentage stayed essentially stable, despite a 10% increase in cancer-related deaths since 1999.

In Japan, the growing use of injectable medications in treating cancer and autoimmune diseases has significantly increased the market for injectable drugs. Albuvirtide, a long-acting injectable HIV medication created domestically and licensed in China in 2018, can aid in treating HIV/AIDS patients there. It is an injectable medication that has received approval from the China Food and Drug Administration. Chinese company Luye Pharma Group stated in March 2019 that it had submitted a new medication application to the US FDA for Rykindo. This injectable medication is anticipated to become the first novel Chinese drug approved by the U.S. FDA.

Six Arab nations comprise the Gulf Cooperation Council (GCC): the United Arab Emirates (UAE), Kuwait, Bahrain, Qatar, the Kingdom of Saudi Arabia, and Oman. The social and economic backgrounds, health problems, and practically equivalent health systems and regulations are shared by GCC nations. The burden of chronic diseases like cancer is anticipated to rise. Brazil's population is expanding, and the country is undergoing a significant change in the private health sector, which is a supporting factor for the market for injectable pharmaceuticals. Over the projection period, the Brazilian market is expected to have a high CAGR. The main factors driving the expansion of the regional market are the rising prevalence of chronic illnesses, the rising elderly population, and rising awareness.

Report Scope

Report Metric Details
By Molecule Type
  1. Small Molecule
  2. Large Molecule
By Drug Class
  1. Blood Factors
  2. Cytokines
  3. Peptide Hormone
  4. Immunoglobulin
  5. Monoclonal Antibodies (MABS)
  6. Insulin
  7. Other Drug Classes
By Applications
  1. Oncology
  2. Neurology
  3. Cardiovascular Diseases
  4. Autoimmune Diseases
  5. Infectious Diseases
  6. Pain
  7. Other Applications
Company Profiles Novo Nordisk AS Amgen Inc. Baxter International Inc. Gilead Sciences Inc. GlaxoSmithKline PLC Johnson and Johnson Merck and Co. Inc. Novartis AG Pfizer Inc. Sanofi SA.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global injectable drugs market is segmented by molecule type, drug class, and application.

Based on molecule type, the global injectable drugs market is bifurcated into small and large molecules.

The large molecule segment is the highest contributor to the market and is estimated to boost at a CAGR of 7.90% during the forecast period. Proteins with a therapeutic impact are classified as large molecules or biologics. These molecules are anticipated to increase as the biopharmaceutical sector sees a constant increase in biologics, orphan medications, and precision medicines. Vaccines, blood, blood components, gene therapy, tissue, and other proteins are large molecular products. The demand for injectable medications is anticipated to increase dramatically as the pace at which biologics are approved rises. Nine novel biologic molecular entities had received FDA Center for Drug Evaluation and Research approval as of December 2021. Biologics and gene treatments significantly contributed to the US FDA medicine approval reaching a record high.

Over the past few years, pharmaceutical corporations and researchers have been more interested in small-molecule medications. Small molecule medications are necessary for situations where the need for quick drug delivery, an emergency, or unanticipated complications, are present. By delivering medication directly into the bloodstream, the intravenous infusion has an instant therapeutic effect. Since these agents can quickly enter cells due to their low molecular weight and size, small-molecule drugs are often created for targets inside the cell. These compounds are primarily employed in targeted therapy for cancer and several other disorders. Small molecule medications have historically been utilized to treat illnesses of the cardiovascular system.

Based on drug class, the global market is bifurcated into blood factors, cytokines, peptide hormones, immunoglobulin, monoclonal antibodies (MABS), insulin, and other drug classes.

 during the forecast period. Monoclonal antibodies are specially crafted proteins that function in the immune systeinjectable drugs marketm like human antibodies. There are four types: humanized, murine, chimeric, and human. Many illnesses, including cancer, infections, and inflammatory diseases, are treated with monoclonal antibodies. Since monoclonal antibodies help treat various ailments, numerous infectious diseases and different types of cancer are on the rise. Therefore, the studied market is anticipated to increase significantly during the forecast period due to the increasing development of MABS for multiple ailments.

Blood proteins known as coagulation factors or blood factors are necessary for a healthy blood clot to form. The liver and blood arteries create a variety of coagulation factors, which are essential to the complicated process of blood clotting. Blood clots can clog blood vessels (an artery or a vein), which can cause significant difficulties because they interrupt the blood supply to vital organs and increase the risk of heart attack and stroke. Coagulation agents are used to treat and prevent blood clots. As mentioned above, one of the main factors influencing the market for the category is the rising frequency of chronic and inherited blood diseases. Blood malignancies and numerous blood disorders can have an impact on an individual.

The collection of peptides, proteins, and glycoproteins known as cytokines includes interleukins, interferons, lymphokines, and monokines, among others. Cytokines are secreted by particular immune system cells. The molecules that control and govern hematopoiesis, immunology, and inflammation will receive cytokine signals. Cytokine-based therapeutics have emerged due to advances in our understanding of the role of cytokines in immunological and inflammatory illnesses. The market players are heavily investing in and starting clinical studies based on cytokine-based therapies, likely to propel the market growth during the forecast period. Several research activities are currently underway to prove the efficacy and role of cytokines in various chronic conditions.

A chain of amino acids called peptide hormone, or peptide therapeutic, performs the role of a biological communication molecule. Peptide hormones, including thyroid hormones and gastrointestinal hormones, among other intracellular signaling peptides and proteins, have systemic and local effects. One of the most debated areas of drug development is the creation of peptide-based medications, typically synthetic analogs of endogenous peptides. For newly developed anti-cancer drugs, the field of peptide therapies has promise. The simplicity, speed, and ability to modify peptides are all advantages of peptide therapies in treating cancer. 

Based on application, the global market is bifurcated into oncology, neurology, cardiovascular diseases, autoimmune diseases, and infectious diseases.

The infectious diseases segment is the highest contributor to the market and is estimated to boost at a CAGR of 6.70% during the forecast period. Pathogenic organisms, such as viruses, fungi, bacteria, or parasites, cause infectious diseases. Human bodies are home to a variety of species. In most cases, they are benign or even beneficial. However, under specific circumstances, some organisms can lead to disease. Rising infectious illness prevalence and increased efforts to raise public awareness of available therapies are anticipated to increase the penetration rate of these diseases' treatments, which is expected to support injectable drugs market expansion. As a result of the factors above, it is anticipated that this market will continue to expand significantly.

The second most significant cause of death worldwide is cancer. According to the International Agency for Research on Cancer (IARC) (December 2020), one in five people will have cancer at some point. Drugs used in oncology and chemotherapy, including doxorubicin, entrada, and carboplatin, are offered as injectables. These aid in avoiding drug degradation brought on by liver metabolism and facilitating the drug's direct entry into the systemic circulation, from which point it can reach particular tissues and exert a therapeutic effect that oral medications cannot. One of the most effective methods for treating cancer is chemotherapy. A crucial component of treating cancer is ensuring that the proper medicine is delivered to the right target at the right time.

The increased need for treating neurological problems is expected to significantly increase injectable medications for neurological purposes. According to 2019 WHO estimate, epilepsy affects about 50 million people worldwide, making up a sizable share of the global illness burden. Around five million people are given epilepsy diagnoses each year, and 80% of those diagnosed with the condition reside in low- and middle-income nations. In 2020, 5.8 million Americans 65 and older will have Alzheimer's dementia, according to the Alzheimer's Association.

Diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn's disease, inflammatory bowel disease, and psoriasis are prevalent conditions typically categorized as autoimmune disorders. The global rise in diabetes prevalence is driving the market's expansion. The need for cutting-edge treatment delivery methods has grown as the prevalence of diabetes rises. Diabetes affected almost 200.6 million individuals in China and India in 2019. Type 1 diabetes was determined to affect 19.84 million persons, whereas Type 2 diabetes affected the remainder.

Market Size By Molecule Type

Market Size By Molecule Type
  • Small Molecule
  • Large Molecule
  • Key Players

    Injectable Drugs Market Share of Key Players

    Injectable Drugs Market Share of Key Players
    Novo Nordisk AS Amgen Inc. Baxter International Inc. Gilead Sciences Inc. GlaxoSmithKline PLC Johnson and Johnson Merck and Co. Inc. Novartis AG Pfizer Inc. Sanofi SA. Others

    Frequently Asked Questions (FAQs)

    What is the market size of injectable drugs in 2031?
    The global injectable drugs market size was valued at USD 924.48 billion in 2031.
    North America has the highest growth rate in the market.
    Key verticals adopting injectable drugs market include: -Novo Nordisk AS, Amgen Inc., Baxter International Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson and Johnson.
    The global injectable drugs market growing at a CAGR of 7.95% from (2023–2031).
    Expanding the use of prefilled syringes for biological products is one of the key trends in the market.

    We are featured on :